Study guide

5.4 Peripheral and Carotid Angiography and Interventions

AACN Cardiac Medicine Certification CMC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview and the CMC Test Plan

1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them

2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease

2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy

3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease

3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup

4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions

4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation

5 Chapter 5: Vascular Conditions and Vascular Interventions

5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications

6 Chapter 6: Shock States and Mechanical Circulatory Support

6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD

7 Chapter 7: Cardiac Procedures and Structural Heart Interventions

7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications

8 Chapter 8: Cardiovascular Pharmacology

8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure

9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary

9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients

10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral

10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients

11 Chapter 11: Monitoring and Diagnostics

11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography

12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions

12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease

5.4 Peripheral and Carotid Angiography and Interventions

Key Takeaways Explain This Topic AI

Carotid revascularization is offered for symptomatic stenosis of 50% or more (ideally within 2 weeks of the index event) and for asymptomatic stenosis of 70% or more when life expectancy is 3-5 years and institutional perioperative stroke/death rates stay under 3% asymptomatic and 6% symptomatic.

Balloon inflation and stent expansion at the carotid bulb stretch the carotid sinus baroreceptor and cause abrupt bradycardia and hypotension; atropine 0.5-1 mg or glycopyrrolate 0.2 mg is drawn up before the case and pacing is available, but the pressure is deliberately not overcorrected.

Cerebral hyperperfusion syndrome presents as ipsilateral throbbing headache, seizure, or focal deficit hours to days after revascularization and can progress to intracerebral hemorrhage; systolic pressure is typically held under 140 mmHg, and under 120 mmHg once the syndrome is suspected.

TCAR reverses carotid flow into a femoral vein shunt before the lesion is ever crossed, delivering embolic protection without aortic-arch catheter manipulation, which is why it is favored over transfemoral stenting in older patients with hostile arch anatomy.

Atherectomy debulks calcified plaque but its signature complication is distal embolization, so pedal Doppler signals are documented immediately before and immediately after the intervention and embolic protection filters are frequently deployed.

Last updated: August 2026

Peripheral Angiography: Indications and Access

Test-plan items III.B.1 (peripheral angiography and intervention) and III.B.2 (carotid angiography and intervention) both live inside Therapeutic Interventions, the 39% domain. The CMC candidate is not asked to select the device. The candidate is asked what changes at the bedside because the patient had one.

Digital subtraction angiography (DSA) of the peripheral circulation remains the reference standard when intervention may occur in the same sitting. Indications include chronic limb-threatening ischemia with rest pain or tissue loss, lifestyle-limiting claudication that has failed supervised exercise therapy and optimal medical therapy, acute limb ischemia, a failing or thrombosed bypass graft, renal or mesenteric artery stenosis, and evaluation of an access-site injury after cardiac catheterization or mechanical circulatory support.

Access Routes and What They Mean for Nursing

Route Typical use Nursing implications

Common femoral (retrograde or antegrade) Workhorse for aortoiliac and infrainguinal work; accommodates large sheaths Highest retroperitoneal hematoma risk, driven by a puncture above the inguinal ligament. Flat bed rest 2-6 hours depending on sheath size and closure method

Radial or brachial Increasingly used for iliac and even superficial femoral artery work with long-shaft devices Radial: patent hemostasis band, no blood pressure cuff, venipuncture or IV in that arm. Brachial has higher hematoma and median nerve injury rates than radial because it cannot be compressed against bone

Pedal or tibial retrograde Crossing a below-knee chronic total occlusion after an antegrade attempt fails Small-vessel spasm is common; monitor forefoot perfusion and a distal puncture site that is easy to overlook

Popliteal Retrograde crossing of a superficial femoral artery occlusion Prone or lateral positioning during the case; assess for popliteal fossa hematoma and new peroneal nerve symptoms (foot drop)

Contrast Load and the Renal Patient

A peripheral runoff study consumes far more contrast than a coronary angiogram because the entire aorta-to-foot tree is imaged in stations. Nursing priorities are to know the baseline creatinine and eGFR, provide isotonic saline hydration before and after, hold metformin per policy, help minimize total contrast volume, and trend urine output and creatinine at 24-72 hours.

Carbon dioxide (CO2) angiography is the alternative below the diaphragm in advanced chronic kidney disease or severe contrast allergy: CO2 gas is injected as the contrast agent, displaces blood, and is absorbed and exhaled. It is contraindicated above the diaphragm and in the cerebral circulation because of gas embolism risk. Patients frequently report transient cramping, an urge to move, or a strange sensation during injection — warn them, because an unprepared patient moves and ruins the run.

Runoff describes how many of the three tibial vessels — anterior tibial, posterior tibial and peroneal — remain patent to the foot. Poor runoff predicts poor durability of any proximal intervention and is often the reason a patient returns to the lab weeks later.

Endovascular Therapy Options and Why Location Decides

Device Mechanism Where it is favored What the nurse watches for

Plain balloon angioplasty Fractures and displaces plaque, stretching the vessel wall Below-the-knee vessels and small arteries where a stent would be crushed Dissection, elastic recoil, early restenosis

Drug-coated balloon (DCB) Paclitaxel or sirolimus transferred to the vessel wall with no metal left behind Femoropopliteal disease; preserves future treatment options Requires good vessel preparation. The FDA concluded in July 2023 that the earlier paclitaxel late-mortality signal is no longer supported by the totality of the data

Self-expanding nitinol or balloon-expandable bare-metal stent Mechanical scaffold after dissection or recoil Aortoiliac disease, where durability is excellent; long superficial femoral artery lesions Stent fracture in the mobile femoral segment; stents are avoided across the hip and knee joints

Drug-eluting stent Antiproliferative drug plus scaffold Focal superficial femoral and proximal tibial lesions In-stent restenosis; antiplatelet duration

Covered stent-graft PTFE-lined scaffold that excludes the wall Perforation or rupture rescue, aneurysm, in-stent restenosis Covers side branches, so watch for new territory ischemia

Atherectomy — directional, rotational, orbital, laser Excises, sands, or ablates plaque to debulk it Heavily calcified lesions; common femoral artery and bifurcations where leaving a stent is undesirable; below-the-knee vessels Distal embolization is the signature complication , which is why embolic protection filters are frequently used. Also perforation and dissection. Document pedal Doppler signals immediately before and after

Lesion Location Drives the Strategy

Aortoiliac disease — primary stenting is first-line with excellent long-term patency; kissing stents are used at the aortic bifurcation. These are the highest-flow, most durable results in the peripheral tree.

Femoropopliteal disease — the mobile segment, subject to flexion, torsion and compression. Drug-coated balloon with provisional (bailout) stenting, or a drug-eluting stent for a focal lesion. Avoid crossing the knee.

Infrapopliteal (tibial) disease — intervened on for limb salvage, not for claudication. Plain balloon angioplasty and increasingly drug-coated devices, targeting the angiosome that feeds the wound so the treated vessel actually perfuses the ulcer.

Medical therapy does not stop because a stent went in: high-intensity statin, single or dual antiplatelet therapy per lesion and device, smoking cessation, glycemic and blood pressure control, and supervised exercise all continue. Patency of an intervention is not a cure for atherosclerosis, and reinforcing that is a nursing teaching priority.